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Abstract
Most human cancers contain mutations in the transcription factor p53 and majority of these are
missense and located in the DNA binding core domain. In this study, the stabilities of all core
domain missense mutations are predicted and are used to infer their likely inactivation mechanisms.
Overall, 47.0% non-PRO/GLY mutants are stable (ΔΔG < 1.0 kT) and 36.3% mutants are unstable
(ΔΔG > 3.0 kT), 12.2% mutants are with 1.0 kT < ΔΔG < 3.0 kT. Only 4.5% mutants are with no
conclusive predictions. Certain types of either stable or unstable mutations are found not to
depend on their local structures. Y, I, C, V, F and W (W, R and F) are the most common residues
before (after) mutation in unstable mutants. Q, N, K, D, A, S and T (I, T, L and V) are the most
common residues before (after) mutation in stable mutants. The stability correlations with
sequence, structure, and molecular contacts are also analyzed. No direct correlation between
secondary structure and stability is apparent, but a strong correlation between solvent exposure
and stability is noticeable. Our correlation analysis shows that loss of protein-protein contacts may
be an alternative cause for p53 inactivation. Correlation with clinical data shows that loss of stability
and loss of DNA contacts are the two main inactivation mechanisms. Finally, correlation with
functional data shows that most mutations which retain functions are stable, and most mutations
that gain functions are unstable, indicating destabilized and deformed p53 proteins are more likely
to find new binding partners.
PACS codes: 87.14.E-
1. Introduction
p53 is a transcription factor involved in DNA repair,
growth arrest and apoptosis [1-3]. It plays a critical role in
cell responses to many cancer-causing events. Upon acti-
vation of certain oncogenes, p53 can stop cell cycle and
induce apoptosis [1-3]. It has been reported that 50% of
human cancers contain mutations in p53 [4], among
which 95% are in the DNA-binding core (DBC) domain
[4]. More interestingly 75% of DBC mutations occur as
single missense mutations [4], i.e. most cancer mutants
are full-length proteins. This finding holds the promise of
a new therapy, which intends to restore apoptosis in can-
cer cells by activating the full-length p53 [5].
The crystal structure of Cho et al offers the first hints for
the molecular mechanisms of cancer mutations in the
DBC domain [6]. Their structure shows that residues most
frequently mutated in cancer are at or near the protein-
DNA interface [6]; the two most frequently mutated resi-
dues (R248 and R273) directly contact DNA [6]; the
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remaining four hot spot residues (R175, R249, R282 and
G245) appear to play a critical role stabilizing the struc-
ture of the DNA binding interface [6]. Based on Cho et al's
structure, Bullock et al analyzed a wide range of missense
mutants focusing on protein folding stability and DNA
binding affinity [7,8]. They found that mutation sites
causing loss of protein stability are mostly located in the
beta-sandwich and Zinc-binding region, and mutation
sites causing loss of DNA binding are at or near the DNA-
binding interface [7,8]. Their analysis shows that a large
fraction of cancer mutations may reduce stability of the
DBC domain, resulting in loss of p53 functions at the
body temperature. Thus, it is crucial to understand stabil-
ity changes upon mutations in the DBC domain. To date
only about 30 cancer mutants have been measured and
analyzed [7-10], but about 1,300 different mutations have
been reported for the DBC domain in cancer patients [4],
among which about 1,000 mutations are missense.
In this work, we intend to analyze the stabilities and
molecular contacts of all missense cancer mutations in the
DBC domain to infer their likely molecular mechanisms.
We have first validated the accuracy of three independent
theoretical methods for protein stability prediction, PBSA
[11], DFIRE [12], and FOLDX [13] with respect to meas-
ured relative stabilities for the DBC domain [7-10] before
a comprehensive stability prediction is made for missense
cancer mutants in the IARC database [4]. Based on the
comprehensive stability prediction, we have analyzed the
stability correlations with sequence, structure, and molec-
ular contacts, and the correlations with clinical and func-
tional data.
2. Results and Discussion
2.1. Overview of Relative Stabilities by Missense Mutations
All IARC missense cancer mutations in the DBC domain,
codons 96 to 289, are subject to three independent analy-
ses by PBSA [11], DFIRE [12], and FOLDX [13]. Among a
total of 1,006 missense mutations, 642 can be analyzed
quantitatively, 152 mutations result in structural clash in
homology models (see Method) or loss of Zinc binding,
and 212 mutations involves PRO (from or to) and GLY
(from). The last two groups of mutants can only be ana-
lyzed qualitatively. All computed relative stabilities are
given in Additional file 1. In our analysis, a mutation is
predicted to be stable (or unstable) only when at least two
of the three predictions are consistent with each other.
Among the 642 mutations analyzed quantitatively, 373
mutations are stable, i.e. ΔΔG ≤ 1 kT – at least 98% folded
at 37°C (1 kT ≈ 0.6 kcal/mol, k is Boltzmann constant,
and T is thermodynamic temperature); 136 are unstable,
i.e. ΔΔG > 3 kT – at most 85% folded at 37°C; 97 muta-
tions are with relative stabilities between 1 kT and 3 kT,
i.e. mutations in the grey zone; and 36 mutants have
inconsistent predictions by the three methods. Overall,
we find 373 (36.3%) out of 794 non-PRO/GLY mutants
(47.0%) are stable, 288 mutants are unstable (including
Zinc-binding and clash mutants, see Method), 97 mutants
(12.2%) are in the grey zone, and 36 mutants (4.5%) are
without consistent predictions. Following the works of
Fersht and co-workers [9,10], highly stable mutants (ΔΔG
≤ -3 kT) are also identified in the hope to use these as sup-
pressor mutations (Table 1). Nevertheless, a more logical
approach in search of suppressor mutations would be to
analyze the mutation space of the DBC domain systemat-
ically, which is actively under way in this group. In the fol-
lowing, only single missense mutations are analyzed (17
multiple mutations are excluded).
2.2. Missense Mutation Matrix
Fractions of unstable and stable mutations are shown in
Table 2 and Table 3, respectively. In Table 2, the mutation
matrix shows that 13 mutation patterns (V→W, V→E,
I→S, I→T, I→F, I→N, F→C, Y→S, Y→C, Y→H, Y→D,
Y→N, and R→W) are always unstable, indicating their
loss of stability is less likely due to local structural envi-
ronments. Finally, Y (87.5%), I (72%), C (70%), V (67%),
F (62.5%) and W (60%) are the most common amino
acids before mutation in unstable mutants. W (94%), R
(58%) and F (56%) are the most common amino acids
after mutation in unstable mutants.
Table 3 shows the fractions of stable mutations. We found
that 10 types of mutations (S→G, S→A, S→C, S→T, F→Y,
Y→F, K→T, D→A, N→T, and Q→E) are always stable.
These stable mutations do not depend on their environ-
Table 1: Highly stable mutations (ΔΔG ≤ -3 kT) and their predicted relative stabilities by PBSA, DFIRE, and FOLDX, respectively.
MUTANTS SEC. ΔΔG (PBSA) ΔΔG (DFIRE) ΔΔG (FOLDX) No. CASE.
A159V S4 -2.27 -1.83 -1.49 41
A161V S4 -3.51 -1.98 -1.14 12
N235I S8 -2.85 -1.68 -2.04 5
N239Y L3 -2.36 -2.41 -2.17 8
T256I S9 -1.22 -1.96 -1.84 3
S269I S10 -1.95 -1.99 -0.91 1
The unit of ΔΔG is in kcal/mol. Second column shows secondary structure elements. The last column gives the number of reported cases in the 
IARC database.PMC Biophysics 2009, 2:5 http://www.physmathcentral.com/content/2/1/5
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ment. Finally, Q (78%), N (73%), K (71%), D (70%), S
(67%), T (67%) and A (66%) are the most common
amino acids before mutation in stable mutants. I (76%),
T (72%), L (63%) and V (62%) are the most common
amino acids after mutation in stable mutants.
2.3. Correlations between Sequence/Structure and 
Stabilities
Stability distribution over sequence is shown in Fig. 1. It
can be found that certain mutation sites are always stable
or unstable no matter what amino acids are involved. Sites
with more than 50% unstable mutations are defined as
unstable below. Stable sites are also defined similarly. Fig.
2A shows surface distributions of stable and unstable
sites, colored by blue and red, respectively. It is interesting
to note that many stable sites are far from the DNA bind-
ing region. These mutations are less likely to disrupt DNA
binding. Thus folding stability and binding affinity are
probably not the only mechanisms for p53 inactivation
by missense mutations. The likely causes of inactivation
by these stable missense mutations will further be dis-
cussed below. Distributions of stable and unstable sites
Table 2: Fractions of unstable mutants (> 3 kT) from codons 96 to 289 before and after substitution.
GAVLI SC T M FY W H KR D E NQ A L L
A 0/4 1/6 0/4 1/7 1/1 3/7 0.21
V 10/12 7/12 6/12 1/6 6/8 3/5 3/3 3/5 9/9 0.67
L 0/9 0/3 0/1 0/5 3/6 2/4 6/8 4/6 0.36
I0 / 6 1 / 4 6/6 6/6 1/3 6/6 1/1 1/1 6/6 0.72
S 0/7 0/3 1/2 1/5 0/11 0/10 1/7 2/3 1/1 2/6 1/5 0.15
C 5/8 0/1 4/10 0/1 6/7 7/9 7/8 1/1 9/10 0/1 0.70
T 0/10 2/11 0/8 1/3 1/5 1/2 0/6 0.11
M 0/6 1/5 1/6 2/5 4/6 3/4 0.34
F 1/1 2/4 3/5 1/3 4/5 4/4 0/2 0.625
Y1 / 1 6/6 6/6 0/5 7/7 1/1 7/7 6/6 1/1 0.875
W 1/1 0/1 1/1 0/1 1/1 0.60
H 0/1 2/5 2/7 4/6 1/6 1/4 2/6 0.34
K 0/1 0/3 0/3 1/1 1/5 1/4 0/4 1/3 0.17
R 3/15 0/12 1/3 2/13 0/9 2/4 0/2 1/1 1/2 6/6 3/10 1/4 1/2 3/8 0.26
D 0/7 0/3 1/8 0/1 2/8 2/7 1/1 0/7 0/8 0.12
E 2/11 0/9 0/10 0/2 5/11 1/1 1/10 1/8 0.16
N 1/8 0/9 0/7 0/1 1/1 3/6 2/6 0/6 1/8 0.15
Q 2/5 1/6 0/4 0/6 0/2 0.13
ALL 0.34 0.18 0.08 0.30 0.17 0.365 0.32 0.26 0.32 0.56 0.47 0.94 0.44 0.34 0.58 0.39 0.45 0.36 0.375
First column shows residues before mutation and first row shows residues after mutation. Each element means fraction of unstable mutations. For 
example, there are a total of 3 mutations from I to M, only one of them is unstable. There are a total of 6 mutations from Y to S. All of them are 
unstable. Elements with 100% unstable mutations are highlighted in bold. The last column shows the percentage of total unstable mutations from a 
given WT amino acid. For example, mutations from WT V residue result in 67% unstable core domain. The last row shows the percentage of total 
unstable mutations to a given amino acid. For example, 94% mutations to W are unstable.PMC Biophysics 2009, 2:5 http://www.physmathcentral.com/content/2/1/5
Page 4 of 10
(page number not for citation purposes)
over secondary structures are shown in Fig. 2B. Visual
inspection does not lead to noticeable correlation
between secondary structures and stabilities. Finally Fig. 3
shows side chain exposures of unstable and stable sites,
respectively. Not surprisingly almost all unstable sites are
buried. This is consistent with the fact that most buried
sites are hydrophobic so that mutations at these sites
mostly disrupt hydrophobic packing. Indeed 93% unsta-
ble sites are buried by more than 80%, and 86% are bur-
ied by more than 90%. In contrast, most stable sites are
exposed and 82% stable sites are exposed by more than
20%.
2.4. Correlation between Molecular Contacts and 
Stabilities
As shown above many stable cancer mutations are far
from the DNA binding region. One possible reason that
these DBC mutations inactivate p53 may be loss of pro-
tein-protein contacts with other p53 domains, with its
tetramer subunits, or with its binding partners. It has been
pointed out that specific p53-DNA binding is highly
cooperative and involves interaction of p53 not only with
the DNA, but also with other tetramer subunits [14]. Thus
protein-protein interactions are critical in the formation
of a stable p53-DNA complex, and have been implicated
Table 3: Fractions of stable mutants (< 1 kT) from codons 96 to 289 before and after substitution.
GAV L I S C T MFY W HKRDENQA L L
A 2/4 5/6 3/4 6/7 0/1 3/7 0.655
V 1/12 1/12 6/12 5/6 1/8 1/5 0/3 2/5 0/9 0.24
L 5/9 2/3 1/1 1/5 3/6 1/4 1/8 0/6 0.33
I 0/6 3/4 0/6 0/6 1/3 0/6 0/1 0/1 0/6 0.10
S 7/7 3/3 1/2 4/5 11/11 10/10 6/7 1/3 0/1 4/6 3/5 0.67
C 1/8 0/1 3/10 1/1 0/7 2/9 0/8 0/1 1/10 0/1 0.14
T 9/10 9/11 3/8 2/3 3/5 1/2 3/6 0.67
M 5/6 4/5 5/6 2/5 1/6 1/4 0.56
F 0/1 1/4 1/5 1/3 1/5 0/4 2/2 0.25
Y 0/1 0/6 0/6 5/5 0/7 0/1 0/7 0/6 0/1 0.125
W 0/1 0/1 0/1 0/1 0/1 0.0
H 1/1 3/5 5/7 2/6 2/6 2/4 3/6 0.51
K1 / 1 3/3 2/3 0/1 4/5 2/4 3/4 2/3 0.71
R 3/15 11/12 1/3 4/13 5/9 2/4 1/2 0/1 1/2 0/6 5/10 3/4 0/2 3/8 0.43
D3 / 7 3/3 6/8 1/1 5/8 4/7 0/1 6/7 7/8 0.70
E 4/11 6/9 8/10 1/2 4/11 0/1 6/10 4/8 0.53
N7 / 8 8 / 9 7/7 1/1 0/1 2/6 3/6 4/6 6/8 0.73
Q 3/5 5/6 3/4 5/6 2/2 0.78
ALL 0.31 0.58 0.62 0.63 0.76 0.365 0.52 0.74 0.36 0.38 0.47 0.0 0.44 0.47 0.38 0.43 0.45 0.43 0.375
First column shows residues before mutation and first row shows residues after mutation. Each element means fraction of stable mutations. 
Elements with 100% stable mutations are highlighted in bold. The last column shows the percentage of total stable mutations from a given WT 
amino acid. The last row shows the percentage of total stable mutations to a given amino acid. See Table 2 for more detail.PMC Biophysics 2009, 2:5 http://www.physmathcentral.com/content/2/1/5
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in DNA binding and the architectural accommodation of
four DBC domains to a single recognition element
[14,15]. In addition, the tetramer DBC domain is stabi-
lized both by interactions within each dimer and by inter-
actions between dimers [16]. Such interactions are critical
in stabilizing functional p53-DNA complexes in cases
where specific DNA interactions are diminished as a result
of truncated DBC domains [16]. Fig. 4 shows molecular
contact (DNA contacts also listed) distributions of the
p53 DBC domain based on crystal structures [16-19].
Here two residues are defined to be in contact when any
atom in one residue is within 6 Å of any atom in the other
residue. Many molecules are know to bind p53 but no
complex structures are available [20-25]. This limits our
molecular contact analysis. Thus only contacts observed
in available structures are analyzed and shown in Fig. 4.
Nevertheless, 57.3% stable sites are for protein or DNA
contacts (25% for protein-only contacts, 19.1% for DNA-
Stability distribution of IARC missense mutations from codons 96 to 289 Figure 1
Stability distribution of IARC missense mutations from codons 96 to 289. Symbols in Italic Times: wild type amino 
acids; those in Normal Times: mutant amino acids; and those in Bold Times: secondary structures. Red grids: mutations with 
relative stabilities larger than 3 kT (including clash and Zinc-binding). Blue grids: mutations with relative stabilities less than 1 
kT. Grey grids: mutations with relative stabilities between 1 kT and 3 kT. Mauve grids: mutations from or to PRO and from 
GLY. Yellow grids: mutations without consistent predictions.
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only contacts, 13.2% for both protein and DNA contacts).
These data imply that loss of protein contact may be a rea-
son for p53 to lose its function upon stable mutations far
from the DNA binding region.
All PRO/GLY sites are highly conserved in all mammalian
p53 DBC domains so that their roles in structural integrity
of the DBC domain can be assumed to be highly impor-
tant. Existing DBC domain structures [6,16] are consistent
with this assumption. Indeed measurements by the Fersht
group show that P151S is 4.49 kcal/mol and G245S is
1.21 kcal/mol less stable than the WT DBC domain [7].
From Fig. 4, it can be found that many PRO and GLY sites,
especially GLY sites (53.8%), are also involved in molecu-
lar contacts.
We found that most protein-protein contact sites (44.1%)
are stable (Fig. 4). Consistent with previous analysis from
the Fersht group [7,8], most DNA contact mutations
(53.7%) are also stable (Fig. 1 &4). However, a few muta-
tions are both in contact with DNA and unstable. Com-
bining Fig. 1 and Fig. 4, it can be concluded that p53
inactivation may be due to: 1) loss of stability; 2) loss of
DNA contact, protein-protein contact, or Zinc contact; 3)
loss of stability and loss of DNA/protein-protein contact.
Note that the above classification still cannot cover all
missense cancer mutants. This results from our limited
accuracy in stability prediction and limited structural data
in molecular contact analysis. Nevertheless, it is clear that
to activate p53 missense cancer mutants, we need to
restore not only stability but also molecular contacts,
especially protein-protein contacts.
2.5. Correlations between Cancer Types/Functions and 
Stabilities
Finally we present the distributions of unstable or stable
mutations in different cancers in Fig. 5. It can be found
that most reported clinical cases contain unstable muta-
tions. Since many stable mutations are in contact with
DNA (see Fig. 4) (32.3%), loss of protein folding stability
and DNA binding affinity are the main mechanisms in
cancers involving missense mutations, consistent with the
previous experimental annotation efforts by the Fersht
group. Fig. 6 shows the percentages of unstable or stable
mutations in functional analysis of missense mutations.
Not surprisingly, most mutations that retain functions are
stable (35.7%). Interestingly most mutations that gain
functions are unstable (55.4%), indicating destabilized
and deformed p53 proteins are more likely to find new
binding partners. It is worth to point out that the interplay
between stability and function is quite general in biomo-
lecular recognition as analyzed in a recent theoretical
study [26].
2.6. Limitations
Finally, it is necessary to discuss the limitations of the pure
thermodynamics analysis that was utilized here for effi-
ciency. Indeed, the effect of mutations on folding kinetics
cannot be captured with thermodynamics analysis alone.
Recent studies by Mahanty et al. [27,28] suggest muta-
tions may interfere with folding kinetics even if they can
increase stability. Thus whether stabilized mutations
eventually lead to functionally more robust protein can-
not be understood with the thermodynamics analysis
alone [29-31].
3. Methods
Protein stability change upon mutation is defined as the
folding free energy difference between a mutant protein
(MT) and the wild type protein (WT):
ΔΔ Δ Δ Δ Δ GG G G G =−= − −−
−−
ND
MT
ND
WT
N
MT WT
D
MT WT.
Surface distribution of stable sites (in blue) and unstable sites  (in red) (A, left).  Figure 2
Surface distribution of stable sites (in blue) and 
unstable sites (in red) (A, left). Secondary structure dis-
tribution of stable sites (in blue) and unstable sites (in red) (B, 
right).
   
Side chain exposures of unstable sites (A, left) and stable  sites (B, right) Figure 3
Side chain exposures of unstable sites (A, left) and 
stable sites (B, right).
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Here, the folding free energy of a protein is the free energy
difference between its native state (N) and denatured state
(D): Δ G'N-D = G'N-G'D, with ' = MT or WT Prediction of
protein stabilities has attracted much attention in compu-
tational biology with many computational models pro-
posed [12,32-35] that take into account various factors
important for protein stability [36-41].
In this work, we have chosen three well-established com-
putational methods to predict protein stability change
upon mutations. The first method is PBSA [11,42-44] that
can be used to estimate stability if we assume hydropho-
bic and electrostatic (salt-bridge) interactions are the pre-
dominant components in stabilizing proteins. Here the
hydrophobic free energy is estimated by a term linearly
proportionally to the solvent accessible surface area (SA),
and the electrostatic free energy is computed by solving
the Poisson-Boltzmann (PB) equation [45]. Similar to
protein pKa computations, the protein dielectric constant
is set to be 20 to address electronic polarization, rota-
tional polarization, and ionization effect. [46-48] The sol-
vent dielectric constant is 80. The solvent ionic strength is
set to be 150 mM. All calculations were performed at tem-
perature 283 K. The second method is DFIRE by Zhou and
Zhou [12] who have constructed a new residue-specific
all-atom potential of mean force from nonhomologous
protein structures with their proposed new reference state.
The third method is FOLDX by Guerois et al [13] who
have developed an efficient all-atom free energy function
with weighted free energy terms trained using empirical
data from experimental stabilities. After a control study of
three models with available experimental data for the
DBC domain, we use all three methods to comprehen-
sively analyze the missense cancer mutants in the IARC
database.
Crystal structure (codons 96 to 289), b chain of 1TSR [6]
is used for the native state of the p53 DBC domain.
Homology models are obtained by SCWRL3 [49] for the
native state of missense mutants. If necessary, the dena-
tured state is modeled as a tripeptide centered at the muta-
tion site.
In this work, mutations causing structural clash and dis-
ruption of Zinc binding-sites (176, 179, 238, and 242) are
assumed to be unstable by more than 3 kT. Indeed, these
mutants are generally more unstable as observed in exper-
iment (with ΔΔG ranging from 2.75 to 4.78 kcal/mol for
F134L, V157F, H168R, R175H, M237I, I255F, R282W,
T123A, H168R, and C242S [7,9,50]. Mutations from
PRO/GLY and mutations to PRO are not covered in quan-
titative analysis because such mutations generally cause
significant backbone entropy changes that cannot be
modeled without time-consuming molecular dynamics
analysis. However, they are analyzed qualitative based on
sequence comparison of all mammalian p53.
Distribution of molecular contacts Figure 4
Distribution of molecular contacts. The DNA contacts (as in 2AC0, 2ADY, 2AHI, 2ATA (16)) are denoted by 'DNA', the 
tetramer subunit contacts (as in 2AC0, 2ADY, 2AHI, 2ATA (16)) are denoted by 'p53', the contacts with p53-binding protein 1 
(as in 1GZH (17) and 1KZY (18)) or 2 (as in 1YCS (19)) are denoted by 'BP1' or 'BP2', respectively. Unstable sites are shown 
by red grids; stable sites by blue grids; Pro/Gly residues on wild type by mauve grids.
 
                                                      p 5 3   p 5 3   p 5 3  
  p53  p53    p53                  DNA DNA DNA DNA DNA DNA DNA DNA DNA     DNA DNA DNA
96  97  98  99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116  117  118  119  120  121  122  123  124  125 126  127  128  129 
 
p53  p53  p53    p53                                    
DNA DNA DNA    DNA    DNA     DNA DNA                         B P 1
130 131 132  133  134  135  136  137  138  139  140  141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
 
  BP2    BP2  BP2            BP2 BP2    BP2                   
  BP1  BP1  BP1  BP1     BP2       BP1 BP1 BP1 BP2   BP1                   
  p53  p53  p53  p53  p53  p53  BP1  BP1    BP1    p53 p53 p53 p53 p53 p53 BP2 BP2 BP2 p53 p53 p53 p53          p53
164  165  166  167  168  169  170  171 172 173  174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197
 
p53  p53  p53  p53                         p53  p53  p53       
198  199  200  201  202  203  204  205  206  207  208  209  210 211 212 213 214 215 216 217 218 219 220 221 222 223 224  225  226  227  228 229 230 231
 
               B P 2   B P 2      B P 2                    
          BP2  BP2  BP1  BP1 BP2 BP2   BP1 BP2                   
          p53  p53  p53  p53  BP1 BP1 BP2 p53  BP1 BP2 BP2                
  DNA        DNA DNA DNA DNA DNA p53 p53 BP1 DNA DNA B P 1 B P 1                
232  233  234 235 236 237 238  239  240  241  242  243  244 245 246 247  248  249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265
 
 
 
        BP2              BP2 BP2       p53 p53   BP1 p53
        DNA DNA DNA DNA DNA    DNA DNA DNA   DNA DNA DNA DNA  DNA DNA
266 267 268 269 270 271 272  273  274  275  276  277  278  279 280 281 282 283 284 285 286 287 288 289PMC Biophysics 2009, 2:5 http://www.physmathcentral.com/content/2/1/5
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Quantitative agreements between experimental data and
theoretical data from PBSA, DFIRE, and FOLDX, respec-
tively, are shown in Fig. 7. Corresponding linear correla-
tion coefficients are 0.91, 0.89 and 0.79, respectively; root
mean square deviations are 0.80, 0.88, 1.25 kcal/mol,
respectively; and unsigned average errors are 0.62, 0.75,
0.98 kcal/mol, respectively. In this work, three qualitative
predictions are used to analyze all missense mutants: 1)
relative stabilities less than 1 kT; 2) relative stabilities
larger than 3 kT; and 3) relative stabilities less than -3 kT
– highly stable mutations. Success rates of these qualita-
tive predictions are also given in Table 4. The overall accu-
racies for the 1 kT prediction are 93%, 85%, and 85% by
PBSA, DFIRE, and FOLDX, respectively; those for the 3 kT
prediction are 96%, 91%, 93%, respectively; and those for
the -3 kT prediction are 98%, 96%, 91%, respectively.
Overall, excellent accuracies can be achieved by the three
theoretical methods.
4. Conclusion
Most human cancers contain mutations in the transcrip-
tion factor p53 and majority of these are missense and
located in the DNA binding core domain. In this study,
the stabilities of all core domain missense mutations are
predicted and are used to infer their likely inactivation
mechanisms. Overall, 47.0% non-PRO/GLY mutants are
stable (ΔΔG < 1.0 kT) and 36.3% mutants are unstable
(ΔΔG > 3.0 kT), 12.2% mutants are with 1.0 kT < ΔΔG <
3.0 kT. Only 4.5% mutants are with no conclusive predic-
tions. Certain types of either stable or unstable mutations
are found not to depend on their local structures. Y, I, C,
V, F and W (W, R and F) are the most common residues
before (after) mutation in unstable mutants. Q, N, K, D,
A, S and T (I, T, L and V) are the most common residues
before (after) mutation in stable mutants. The stability
Percentages of unstable (red), stable and DNA contact  (blue), and stable and no DNA contact (green) mutations at  different tumor sites Figure 5
Percentages of unstable (red), stable and DNA con-
tact (blue), and stable and no DNA contact (green) 
mutations at different tumor sites. Total number of 
mutations is also given by each tumor site.
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Percentages of unstable (red), stable and DNA contact  (blue), and stable and no DNA contact (green) mutations in  different functional properties Figure 6
Percentages of unstable (red), stable and DNA con-
tact (blue), and stable and no DNA contact (green) 
mutations in different functional properties. Retained: 
functional property of the mutant is similar to that of the 
WT; temp: the activity of the mutant is affected by the tem-
perature at which the experiment is performed; domi-neg 
(no): dominant negative activity that the mutant does not 
counteract the effects of the WT under the control of a p53-
responsive element when the two proteins are co-expressed 
in human or yeast cells; domi-neg (yes): the mutant protein 
counteract (or has a partial inhibiting effect on) the activity of 
the WT; lost: the WT functional property is lost by the 
mutant; gain: functional properties displayed by the mutant is 
not displayed by the WT protein. The total number of muta-
tions is given by each functional property.
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Correlations between the three theoretical calculations and  the experimental measurements by the Fersht group Figure 7
Correlations between the three theoretical calcula-
tions and the experimental measurements by the 
Fersht group. From left to right, the figure is for PBSA, 
DFIRE and FOLDX, respectively.
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correlations with sequence, structure, and molecular con-
tacts are also analyzed. No direct correlation between sec-
ondary structure and stability is apparent, but a strong
correlation between solvent exposure and stability is
noticeable. Our correlation analysis shows that loss of
protein-protein contacts may be an alternative cause for
p53 inactivation. Correlation with clinical data shows that
loss of stability and loss of DNA contacts are the two main
inactivation mechanisms. Finally, correlation with func-
tional data shows that most mutations which retain func-
tions are stable, and most mutations that gain functions
are unstable, indicating destabilized and deformed p53
proteins are more likely to find new binding partners.
Additional material
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Additional file 1
Quantitative stability predictions of all missense mutants.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1757-
5036-2-5-S1.dat]
Table 4: Accuracies for qualitative predictions, by PBSA, DFIRE, 
and FOLDX, respectively.
PBSA DFIRE FOLDX
≤ 1 kT TP 91% 83% 89%
TN 96% 87% 81%
ACCU. 93% 85% 85%
> 3 kT TP 100% 100% 90%
TN 93% 87% 96%
ACCU. 96% 91% 93%
≤ -3 kT TP 80% 75% 50%
TN 100% 98% 95%
ACCU. 98% 96% 91%
TP: accuracy for true positive predictions; TN: accuracy for true 
negative predictions; ACCU: accuracy for overall accuracy combining 
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